Aethlon Medical Inc. (AEMD.OB) is the developer of the Hemopurifier®, a first–in–class medical device designed to treat infectious diseases and vaccine resistant viruses. Since January 1, 2008, Aethlon Medical has initiated multiple collaborative efforts to explore the therapeutic potential of the Hemopurifier® with the National Institute of Virology (NIV) in India, the World Health Organization (WHO), and Centers for Disease Control and Prevention.
The Hemourifier® is a novel multi–patented platform technology designed for the single use removal of viral pathogens from blood. This highly complex technology mimics the natural response of clearing infectious viruses and related toxins prior to cell and organ infection. The Hemouifier® can be utilized with portable pumps or within the established infrastructure of dialysis machines located in hospitals and clinics. The company is pursuing commercialization initiatives focused on bioterrorism, evolving pandemic threats, and chronic infectious disease conditions, including Hepatitis–C and HIV.
Aethlon Medical, Inc. is actively pursuing clinical initiatives in the United States and abroad. Domestically, the company is pursuing clinical programs targeting the market clearance of the Hemopurifier® as a countermeasure against bioterrorism threats. Aethlon Medical is continuing to gain clearance for the early commercialization of the Hemopurifier® for infectious diseases in foreign markets.
Let us hear your thoughts: Aethlon Medical, Inc. Message Board